These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33072554)

  • 1. The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis.
    Cai S; Zuo W; Lu X; Gou Z; Zhou Y; Liu P; Pan Y; Chen S
    Front Oncol; 2020; 10():1729. PubMed ID: 33072554
    [No Abstract]   [Full Text] [Related]  

  • 2. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
    Liu YR; Jiang YZ; Yu KD; Shao ZM
    Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The disparities in prognostic prediction and annualized hazard function in different molecular subtypes between young Chinese and White American women with breast cancer.
    Zeng Y; Wang J; Zhong X; Xiang Z; Yang T; Yu S; Dai Z; Xu N; Liu L
    Front Oncol; 2023; 13():1199492. PubMed ID: 37492473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying the relationship between age at diagnosis and breast cancer-specific mortality.
    Johnson HM; Irish W; Muzaffar M; Vohra NA; Wong JH
    Breast Cancer Res Treat; 2019 Oct; 177(3):713-722. PubMed ID: 31297648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
    Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
    Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
    Zheng YZ; Wang L; Hu X; Shao ZM
    Oncotarget; 2015 Sep; 6(26):22985-95. PubMed ID: 26036636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
    Yu KD; Wu J; Shen ZZ; Shao ZM
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database.
    Hou L; Qiu M; Chen M; Li F; Li J; Deng S; Yang Y; Du Z; Yang H
    Gland Surg; 2021 Jun; 10(6):1889-1898. PubMed ID: 34268073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
    Leone J; Hassett MJ; Freedman RA; Tolaney SM; Graham N; Tayob N; Vallejo CT; Winer EP; Lin NU; Leone JP
    JAMA Oncol; 2024 Apr; 10(4):508-515. PubMed ID: 38421673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
    Hanrahan EO; Gonzalez-Angulo AM; Giordano SH; Rouzier R; Broglio KR; Hortobagyi GN; Valero V
    J Clin Oncol; 2007 Nov; 25(31):4952-60. PubMed ID: 17971593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical Delay-Associated Mortality Risk Varies by Subtype in Loco-Regional Breast Cancer Patients in SEER-Medicare.
    Leslie M; Pathak R; Dooley WC; Squires RA; Rui H; Chervoneva I; Tanaka T
    Res Sq; 2024 Apr; ():. PubMed ID: 38659868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes.
    Wang C; Chen Z; Zhou Y; Huang W; Zhu H; Mao F; Lin Y; Zhang Y; Guan J; Cao X; Sun Q
    Gland Surg; 2021 Mar; 10(3):943-952. PubMed ID: 33842238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
    Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
    Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
    Leone JP; Leone BA; Tayob N; Hassett MJ; Leone J; Freedman RA; Tolaney SM; Winer EP; Vallejo CT; Lin NU
    Breast Cancer Res Treat; 2021 Jun; 187(3):843-852. PubMed ID: 33590387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
    Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
    Leone JP; Graham N; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Leone J; Vallejo CT; Winer EP; Lin NU; Tayob N
    Eur J Cancer; 2022 Sep; 173():20-29. PubMed ID: 35841843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cause-specific mortality among patients with different molecular subtypes of T1-2N0M0 breast cancer: A population-based study.
    Wang D; Yi L; Zhang L; Wang Z
    Medicine (Baltimore); 2021 Oct; 100(43):e27605. PubMed ID: 34713838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study.
    Bao J; Yu KD; Jiang YZ; Shao ZM; Di GH
    PLoS One; 2014; 9(4):e94815. PubMed ID: 24740002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.